Streetbeat News

Analyst Ratings

ZIMV

Needham analyst David Saxon maintains a Buy rating on ZimVie (NASDAQ:ZIMV) and raises the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 10:04 am

PCTY

Needham analyst Scott Berg reiterates a Buy rating on Paylocity Holding (NASDAQ:PCTY) and maintains a $200 price target.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:58 am

BHC

Piper Sandler has downgraded Bausch Health Companies (NYSE:BHC) from Neutral to Underweight and lowered the price target from $9 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:57 am

AXTI

Needham analyst Charles Shi reiterates a Buy rating on AXT (NASDAQ:AXTI) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:55 am

OCSL

Oppenheimer analyst Mitchel Penn has downgraded Oaktree Specialty Lending (NASDAQ:OCSL) from Outperform to Perform and lowered the price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:54 am

UPLD

Needham analyst Scott Berg has reiterated a Hold rating on Upland Software (NASDAQ:UPLD).

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:51 am

RMD

Needham analyst Mike Matson has reiterated a Buy rating on ResMed (NYSE:RMD) and maintained a price target of $236.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:48 am

MMSI

Needham analyst Mike Matson maintains a Buy rating on Merit Medical Systems (NASDAQ:MMSI) and raises the price target from $93 to $94.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:43 am

RANI

Oppenheimer has initiated coverage on Rani Therapeutics Holdings (NASDAQ:RANI) with an Outperform rating and a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:42 am

SPT

Needham analyst Scott Berg has reiterated a Buy rating on Sprout Social (NASDAQ:SPT) and maintained a $55 price target.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 9:40 am